Gemcabene is under clinical development by NeuroBo Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Gemcabene’s likelihood of approval (LoA) and phase transition for Osteoarthritis took place on 20 Nov 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Gemcabene Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Gemcabene overview

Gemcabene calcium is under development for the treatment of osteoarthritis, hypertension, homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH, non-alcoholic steatohepatitis, non alcoholic fatty liver disease, familial partial lipodystrophy (FPL) disease and non-familial hypercholesterolemia in ASCVD patients. The therapeutic candidate is administered through oral route. It regulates the lipid level. It was also under development for the treatment of mixed dyslipidemia and hypertriglyceridemia.

The company reported that it is also under development for acute COVID-19 indication caused by SAR-COV-2.

It was under development for the treatment of familial chylomicronemia sndrome (FCS).

NeuroBo Pharmaceuticals overview

NeuroBo Pharmaceuticals (NeuroBo), formerly Gemphire Therapeutics Inc, is a clinical stage biopharmaceutical company that focuses on developing novel therapeutics for neurodegenerative and cardiometabolic diseases. The company has pipeline product candidates include ANA001, an oral niclosamide formulation developed for moderate coronavirus disease (COVID-19 which is phase 2 clinical trials. Gemcabene for the treatment of homozygous familial hypercholesterolemia (HoFH) and hypertriglyceridemia (SHTG) which is a serious medical condition that increases the risk of life-threatening cardiovascular diseases; NB-01 for painful diabetic neuropathy (PDN); and NB-02 treated for neurodegenerative diseases such as Alzheimer’s disease and tauopathies. The company has research facilities in South Korea. NeuroBo is headquartered in Boston, Massachusetts, the US.

Quick View Gemcabene LOA Data

Report Segments
  • Innovator
Drug Name
  • Gemcabene
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Infectious Disease
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.